Key Highlights

● With a Market Value of under $3 million and fewer than 600,000 shares outstanding, SciSparc sits at the extreme small end of the biotech spectrum, where even minor trades can swing the price.

● SciSparc is an Israel-based specialty clinical-stage pharmaceutical company focused on treatments for disorders of the central nervous system, with a pipeline that has included candidates such as SCI-110 (targeting conditions including Tourette syndrome) and SCI-210 (explored in autism spectrum disorder).

● No single confirmed catalyst explains the modest early-September pullback; at SciSparc's scale, price moves overwhelmingly reflect thin Liquidity rather than fundamental news.

● SciSparc's Market Capitalisation stood at roughly $2.9 million with about 581,000 shares outstanding and a share price near $4.95 in early September 2026.

With a market value of under $3 million and fewer than 600,000 shares outstanding, SciSparc Ltd (NASDAQ:SPRC) sits at the extreme small end of the biotech spectrum, where even minor trades can swing the price. The stock eased back modestly in early September 2026, a move that in a name this thinly capitalised says little on its own. The more meaningful story lies in a flurry of clinical and corporate activity around SciSparc and its affiliated ventures.

Company and Latest Development

SciSparc is an Israel-based specialty clinical-stage pharmaceutical company focused on treatments for disorders of the central nervous system, with a pipeline that has included candidates such as SCI-110 (targeting conditions including Tourette syndrome) and SCI-210 (explored in autism spectrum disorder). In 2026, much of the newsflow has centred on NeuroThera Labs, an affiliated entity in which SciSparc has disclosed a significant Equity stake. NeuroThera has reported launching a Phase IIb clinical trial for a Tourette syndrome treatment at Yale, pursuing FDA Orphan Drug designation, and progressing an SCI-210 autism study. SciSparc, as a foreign private issuer, reports to the SEC through Form 6-K and 20-F filings rather than the quarterly 10-Q filings used by domestic companies, which can make its disclosure cadence less predictable for U.S. investors.

What Is Driving Attention Around SPRC?

No single confirmed catalyst explains the modest early-September pullback; at SciSparc's scale, price moves overwhelmingly reflect thin liquidity rather than fundamental news. The company completed a share consolidation, or reverse split, in late August 2026, which is consistent with its very low share count. Attention around SPRC has instead been driven by the steady stream of announcements tied to NeuroThera Labs, including a completed financing, Patent milestones and clinical-trial progress, and by SciSparc's disclosed stake in that venture.

Key Numbers and Company Position

SciSparc's market capitalisation stood at roughly $2.9 million with about 581,000 shares outstanding and a share price near $4.95 in early September 2026. The company has disclosed holding a substantial minority stake in NeuroThera Labs, which completed a financing during August 2026. Given the nano-cap scale and the recent share consolidation, investors should verify current share counts and cash position directly from SciSparc's filings before relying on any single figure.

What Could Come Next?

Potential catalysts include clinical progress in the NeuroThera-linked Tourette syndrome and autism programs, any FDA orphan drug designation decision, and further developments at affiliated ventures. Updates on SciSparc's own pipeline, its stake valuations, cash position and any financing or strategic transactions could move the stock. Continued Nasdaq listing compliance is also worth monitoring for a company of this size and share structure.

Risks to Watch

As a nano-cap trading with a tiny float, SPRC carries extreme volatility, Liquidity Risk and the potential for large percentage swings on small volume. Reverse splits are often associated with efforts to maintain listing requirements and do not, by themselves, improve fundamentals. Clinical, regulatory and financing risks are acute, dilution is a persistent threat, and reliance on affiliated ventures adds complexity to the story. With so little market value, the company has limited Margin for error, and any adverse development could have an outsized impact on the shares.

SPRC Faces a Funding and Execution Test

SciSparc's modest September dip is largely a function of its nano-cap structure rather than any identified catalyst. The company's narrative in 2026 has been dominated by clinical and financing activity at affiliated NeuroThera Labs, in which it holds a disclosed stake, alongside a late-August share consolidation. Investors may be watching clinical-trial progress, any orphan drug designation decisions, listing compliance and the company's financial position as the developments most likely to matter for SPRC.